eFax® Earns Spot on G2's 2025 Best Software Awards for Healthcare Software Products
LOS ANGELES--(BUSINESS WIRE)-- Consensus Cloud Solutions, Inc. (NASDAQ: CCSI), a leading provider of digital cloud fax and interoperability solutions, today announced its cloud fax platform, eFax ®, has been named to G2's 2025 Best Software Awards, placing #12 on the Best Healthcare Software Products list.
As the world's largest and most trusted software marketplace, G2 reaches 100 million buyers annually. Its annual Best Software Awards rank the world's best software companies and products based on authentic, timely reviews from real users. This recognition solidifies eFax's market leadership as a premier solution for the secure exchange of critical and sensitive information.
"We're honored that eFax® has been recognized in G2's Best Healthcare Software Products list," said Scott Turicchi, CEO at Consensus Cloud Solutions. "Innovating to meet our customers' evolving needs is fundamental to our company's mission. This award is a testament to our dedication to delivering secure, reliable, and high-performing communication solutions that are essential in today's digital landscape, particularly in highly regulated industries like healthcare."
'The stakes for choosing the right business software are higher than ever,' said Godard Abel, co-founder & CEO at G2. 'With over 180,000 software products and services listings and 2.9 million verified user reviews in the G2 marketplace, we're proud to help companies navigate these critical choices with insights rooted in authentic customer feedback. The 2025 Best Software Award winners represent the very best in the industry, standing out for their exceptional performance and customer satisfaction. Congratulations to this year's honorees!'
G2's 2025 Best Software Awards feature dozens of lists, ranking software vendors and products using G2's proprietary algorithm based on G2's verified user reviews and publicly available market presence data. To be eligible for the Best Software Awards, a software company or product must have received at least one approved review during the 2024 calendar year and appear on a G2 Grid®. Scores reflect only data from reviews submitted during this evaluation period.
Read what real users have to say about eFax.
To learn more, view G2's Best Healthcare Software Products list and read more about G2's methodology.
About Consensus Cloud Solutions
Consensus Cloud Solutions, Inc. (NASDAQ: CCSI) is a global leader in digital cloud fax technology. With over 25 years of success with eFax Ⓡ at its core, the company has evolved to be a trusted provider of interoperability solutions, leveraging artificial intelligence and secure data exchange to transform digital information, automate critical workflows, and maximize operational efficiencies. Consensus maintains industry-leading compliance standards, making it a preferred partner for heavily regulated industries including healthcare, the public sector, financial services, insurance, real estate, and manufacturing. For more information about Consensus, visit consensus.com and follow us on LinkedIn.
About G2
G2 is the world's largest and most trusted software marketplace. More than 100 million people annually — including employees at all Fortune 500 companies — use G2 to make smarter software decisions based on authentic peer reviews. Thousands of software and services companies of all sizes partner with G2 to build their reputation and grow their business — including Salesforce, HubSpot, Zoom, and Adobe. To learn more about where you go for software, visit www.g2.com and follow us on X and LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs
Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a leading investment bank, has initiated a 'Buy' rating for Travere Therapeutics, Inc. (NASDAQ:TVTX), with a price target of $30, signaling an upside of around 100%. This confidence in the company underscores its position in the pharmaceutical sector. The company has just announced plans to present three new abstracts underscoring the impact of FILSPARI (sparsentan) in rare kidney disease at the International Podocyte Conference, taking place in Hamburg, Germany. The findings of FILSPARI, showcasing advanced reductions in urinary BAFF and sC5b9, along with dips in the proinflammatory and profibrotic biomarkers, signal a step forward in the treatment of IgAN. A laboratory technician working on a solution of rare diseases, housed in a cholic acid capsule. With net sales of FILSPARI increasing 182% year-over-year and the successful approval of FILSPARI in Europe and the UK, analysts have little doubt about the company's potential. Since the major revenue contribution comes from FILSPARI, the rising popularity and increasing adoption among nephrologists mean that Travere Therapeutics, Inc. (NASDAQ:TVTX) can continue to leverage a product that is quite differentiated. Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company incorporated in 2008. This California-based giant recognizes, develops, and commercializes therapies for people suffering from rare kidney and metabolic diseases in the United States. While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Ethereum Treasury Firm SharpLink Gaming Plunges 70% – But There May Be a Twist
SharpLink Gaming (SBET), a Nasdaq-listed company that is pursuing an ether ETH treasury strategy, tumbled 70% on Thursday in after-hours trading following a fresh filing to the U.S. Securities and Exchange Commission. The company submitted an S-3ASR registration statement, enabling the resale of up to 58,699,760 shares related to its private investment in public equity (PIPE) financing. The Thursday filing allows more than 100 shareholders in the PIPE round to sell their shares, effectively flooding the market and triggering a post-close sell-off, Charles Allen, CEO of BTCS, a publicly-traded firm that's pursuing crypto reserve strategy, explained in an X post and an interview with CoinDesk. The company raised $450 million earlier this month through a PIPE round from a wide range of investors, including ConsenSys, Galaxy, and Pantera Capital, to acquire ETH for its treasury. Ethereum co-founder and ConsenSys CEO Joseph Lubin also joined the firm as board chairman. However, there may be a larger strategy behind the latest move. Allen said in an X post that he thinks the company may have quietly raised up to $1 billion to buy more ETH using an at-the-market (ATM) offering that was previously announced in a May 30 SEC filing. "If they played cards right, they would expect a surprise PR tomorrow with $1B of ETH purchases, which could light the match to reignite the stock," he said. ETH is down 4.1% over the past 24 hours at around $2,650 as bitcoin and the broader crypto markets in retrieving data Sign in to access your portfolio Error in retrieving data
Forbes
2 hours ago
- Forbes
The Chime IPO Will Kickstart A Fintech Investment Comeback
Chris Britt, co-founder and chief executive officer of Chime Financial Inc., during the company's ... More initial public offering at the Nasdaq MarketSite in New York, US, on Thursday, June 12, 2025. Chime launched its IPO with a splash. Shares jumped as much as 59% above the $27 offering price—opening at $43 and closing near $37—marking a bold public debut for the US's largest neobank. With a valuation hovering between $11.6 billion and $15 billion—well below its 2021 private peak of $25 billion—the surge raises the question: Will this trigger renewed investment in neobanks and fintech? Chime's IPO follows strong debuts from fintechs like Circle and eToro. PitchBook's Rudy Yang framed Chime as 'a strategic breakthrough—marking a return of fintech liquidity' after the sector saw VC exit values plummet from $222 billion in 2021 to under $30 billion in the past few years. Chime could be a bellwether for a neobank--and broader fintech--recovery if it: There is another side of the coin: Is Chime's IPO really a pivotal moment for the fintech industry and a validation of the digital-banking model and a template for future bank challengers? No. Chime's debut feels more like a secure base camp than a flag planted atop Everest. It suggests that public markets are open to credible fintech challengers—provided they bring scale, strong unit economics, and realistic valuations. The critical questions for neobanks: 1) Can they diversify revenue beyond interchange (loans, wealth, insurance)? 2) Will macro conditions hold stable enough to sustain IPO markets? 3) Will consumer-trust and customer growth trajectories support future public offerings? The answers are no. There are market factors impacting neobanks that have closed the door to new neobanks coming into the market: 1) Megafintechs have better economics and business models. Among consumers who consider a digital bank or neobank their primary checking account or payments provider, half of them say their primary provider is PayPal or Square Cash App. Neobanks don't just compete with incumbent banks—they compete with the megafintechs, whose platform business models give them scale and revenue diversity. 2) Interchange isn't a reliable revenue source. Relying on interchange runs against consumer behavior trends regarding: 3) The niche affinity play is tough for startups. This strategy requires neobanks to identify a segment's unique financial needs and Be the dominant affinity. Neobanks' claims of how big their affinity groups are misleading because most of us belong to multiple affinity groups. Fintech has entered a new phase—one defined by realism, consumer impact, and long-term value creation. The new phase, however, isn't about bank disruption and displacement--it's about banking industry infrastructure upgrade and replacement. The Chime IPO will help create more VC interest in fintech investment--but that investment won't go to new neobanks. Instead, it will go to startups that bring two things to the financial services industry: 1) AI-driven process reinvention from machine learning, Generative AI, and Agentic AI tools and technologies, and 2) Stablecoin and other cryptocurrency-related payments innovation. The latter may do more to disrupt banks than Chime and other neobanks have done.
